For example, research on delivering a fusion protein consisting of the lysosomal enzyme iduronate 2-sulfatase (IDS) and an anti-human transferrin receptor antibody (JR-141) into the CNS for treating Hunter syndrome has progressed to a phase II clinical trial [7]. The gene discussed is IDS; the disease is mucopolysaccharidosis type 2.